SciVision Biotech Inc.
1786.TW
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.12B
Close$
Share Statistics
| Market cap | $3.12 Billion |
|---|---|
| Enterprise Value | $2.93 Billion |
| Dividend Yield | $1.91 (4.58%) |
| Earnings per Share | $2.24 |
| Beta | 0.46 |
| Outstanding Shares | 74,230,000 |
Return
| Return on Equity | 9.97% |
|---|---|
| Return on Assets | 7.10% |
| Return on Invested Capital | 7.54% |
Valuation & Multiples
| P/E Ratio | 17.16 |
|---|---|
| PEG | -5.43 |
| Price to Sales | 3.79 |
| Price to Book Ratio | 1.74 |
| Enterprise Value to Revenue | 3.3 |
| Enterprise Value to EBIT | 16.84 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$1.04
Average shareholder expectationRevenue Estimate
$175.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About SciVision Biotech Inc.
1,947 employees
CEO: Kai Cheng Han SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation product...